Japan
株式会社Liquid Mine, a promising healthcare startup, is setting new benchmarks in leukemia treatment. Founded in 2019 and headquartered in Japan, this venture emerged from the prestigious 東京大学医科学研究所 (東大医科研).
Liquid Mine's pioneering product, "MyRD," offers a breakthrough in precision medicine by utilizing state-of-the-art genetic analysis technologies. This service aims to rectify the lack of accurate leukemia MRD (minimal residual disease) monitoring methods. MyRD customizes test assays for each patient, factoring in unique genetic mutations to provide precise, individualized treatments and continual relapse monitoring.
The potential of Liquid Mine was underscored by a Seed Round investment on 03 February 2021, involving investors such as Incubate Fund and Plug and Play Japan. These alliances highlight Liquid Mine's capacity to revolutionize leukemia care and appeal to investors eyeing cutting-edge healthcare innovations.
